SEC Form 4 · accession 0000899243-18-024601
Apellis Pharmaceuticals, Inc. · APLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David O. Watson
Officer — General Counsel
Period of report
Sep 14, 2018
Accepted (ET)
Sep 17, 2018 · 5:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492422
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 14, 2018 | M | 32,818 | $2.67 | A | 32,818 | D | |
| Common StockF1 | Sep 14, 2018 | S | 15,776 | $18.784 | D | 17,042 | D | |
| Common StockF2 | holding | — | — | — | 10,000 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.67 | Sep 14, 2018 | M | 32,818 | D | — | Dec 31, 2023 | Common Stock | 32,818 | 27,505 | D |
Explanation of responses
- F1The price reported is a weighted average. The shares were sold in multiple transactions at prices per share ranging from $18.50 to $19.025, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc. ("Apellis"), any security holder of Apellis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
- F3This option was granted on January 1, 2014 and has fully vested.